Could Telix shares be a millionaire-maker stock?

MotleyFool

03/19

It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620226319"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620226319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620226319?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620226319","market":"nz","top_or_hot":-1,"title":"Could Telix shares be a millionaire-maker stock?","media":"MotleyFool","content":"<div>\n<p>It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/\">网页链接</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Telix shares be a millionaire-maker stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Telix shares be a millionaire-maker stock?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MotleyFool</strong><span class=\"h-time small\">2026-03-19 21:30</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/\">MotleyFool</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/","article_id":"2620226319","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/could-telix-shares-be-a-millionaire-maker-stock/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620226319","pubTimestamp":1773927000,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"It's been a wild ride for investors in Telix Pharmaceuticals Ltd  shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing.That kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000?Importantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals.As more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted.This week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.According to TradingView data, all 16 analysts cove","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"Telix股票会成为百万富翁股票吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"It's been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing. \nThat kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000? \nImage source: Getty Images\nA different growth story\nTelix isn't your typical early-stage biotech. The company develops radiopharmaceuticals used in cancer diagnosis and treatment. It operates in a niche combining precision medicine with complex manufacturing and global distribution. \nImportantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals. \nAs more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted. \nThat dynamic can create sharp price swings, as seen recently with Telix shares. But it also offers direct exposure to a high-growth corner of healthcare.\nRevenue is booming\nTelix's latest results show just how quickly the business is expanding.\nLast month, the company reported full-year revenue of US$803 million, up 56% year on year and at the lower end of its upgraded guidance range.\nEven more impressive, it expects to generate between US$950 million and US$970 million in revenue this year. That would push it comfortably beyond the $1 billion mark. \nAt the same time, Telix is continuing to invest heavily in future growth, with research and development spending forecast at US$200 million to US$240 million.\nThis combination of strong revenue growth and continued innovation is exactly what long-term investors in Telix shares want to see.\nMajor opportunity, limited competition\nOne of the most exciting developments is Telix's progress in brain cancer.\nThe company recently submitted a European marketing application for TLX101-Px, an imaging agent designed for glioblastoma — one of the most aggressive and difficult-to-treat cancers. \nThis week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.\nCrucially, there are currently no widely available commercial alternatives. That gives Telix a rare opportunity to address an urgent medical need with limited direct competition.\nIf successful, this could become a meaningful growth driver for Telix shares in the years ahead.\nWhat do analysts think?\nDespite the share price slump, sentiment remains overwhelmingly positive on Telix shares.\nAccording to TradingView data, all 16 analysts covering ASX biotech stock rate it as a buy or strong buy. Average 12-month price targets suggest Telix shares could climb around 95% to $23.97, with the most bullish forecasts pointing to as high as $31.59. This points to a potential upside of more than 150%. \nThat's a remarkable level of confidence for a stock that has fallen so sharply.\nFoolish Takeaway\nThere's no doubt Telix shares carry risk. Biotech stocks are inherently volatile, and success depends on execution, approvals, and market uptake. \nBut with surging revenues, a growing commercial footprint, and exposure to a high-value medical niche, Telix has the ingredients of a powerful long-term growth story. \nIf it can deliver on its pipeline and scale globally, today's weakness could one day look like an opportunity. The kind that patient investors have million-dollar dreams about.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}